NIFEdipine ER

Phase 3Small molecule

MMedical College of Wisconsin

NIFEdipine ER is one of 16 small molecule programs targeting Primary Aldosteronism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary AldosteronismActive, not recruiting

Hypertensive Disorder of PregnancyActive, not recruiting

Hypertension, Pregnancy-InducedRecruiting

Primary AldosteronismPreclinical

Active, not recruiting

Hypertensive Disorder of PregnancyPhase 3

Active, not recruiting

Hypertension, Pregnancy-InducedPreclinical

Recruiting

Competition

Competitive Landscape

17 competitors in Primary Aldosteronism

#DrugCompanyPhaseTrials

Kerendia

Bayer

Approved

6 2

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

3 3

Parlodel

VVeroScience

Approved

1 4

Baxfendy

AstraZeneca

Phase 3

1 5

NIFEdipine ER

MMedical College of Wisconsin

Phase 3

1 6

Aldactone

Pfizer

Preclinical

4 7

Adrenocorticotropic Hormone

Astellas

Preclinical

1 8

Intensive BP Control

SSecond Affiliated Hospital of Nanchang University

Preclinical

1 9

Mineralocorticoid Receptor Antagonists

UUniversity of Pennsylvania

Preclinical

1 10

CS-3150

Daiichi Sankyo

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

Hypertension, Pregnancy-Induced

NCT06220721

Clinical

Trials by Indication[1]

Hypertension3 trials

Labetalol or Nifedipine for Control of Postpartum Hypertension: A Randomized Controlled Trial

Recruiting·NNebraska Methodist Health System·Phase 4·NCT05309460·600 enrolled

Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension

Completed·TThe University of Texas Health Science Center, Houston·Phase 4·NCT05049616·70 enrolled

Amlodipine Versus Nifedipine ER for the Management of Postpartum Hypertension

Completed·PPrisma Health-Upstate·Phase 4·NCT04790279·175 enrolled

Primary Aldosteronism1 trial

Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism

Completed·QQueen Mary University of London·N/A·NCT05686993·15 enrolled

Postpartum Period1 trial

Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period

Completed·—·Phase 4·NCT04236258·94 enrolled

Hypertension, Pregnancy-Induced1 trial

Reducing the Risk of Chronic Hypertension and Improving Vascular Function Following Preeclampsia

Recruiting·MMedical College of Wisconsin·Preclinical·NCT06220721·618 enrolled

Hypertensive Disorder of Pregnancy1 trial

Intensive Postpartum Antihypertensive Treatment to Improve Women's Cardiovascular Health (IPAT Study)

Active, not recruiting·MMedical College of Wisconsin·Phase 3·NCT05687344·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for NIFEdipine ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NIFEdipine ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NIFEdipine ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical College of Wisconsin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: MMedical College of Wisconsin

NIFEdipine ER

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Hypertension3 trials

Primary Aldosteronism1 trial

Postpartum Period1 trial

Hypertension, Pregnancy-Induced1 trial

Hypertensive Disorder of Pregnancy1 trial

References

Drug Info

Quick Facts

Related News